NEWARK, DE — W. L. Gore & Associates, Inc. announced collaborations with ligand technology partners to develop new affinity membrane devices aimed at improving purification processes for biotherapeutic manufacturing.
The company said the partnerships will combine partner-developed ligand technologies with Gore’s membrane platform to expand purification solutions across applications including cell and gene therapies and antibody-based treatments.
The affinity membrane devices are designed to increase productivity, scalability, and cost efficiency while reducing operational risks in downstream bioprocessing.
Gore said the products will be marketed and distributed either by the company or its partners under their respective brands.
“At Gore, we are committed to helping our customers accelerate the discovery, development, and delivery of vital therapies,” said Russ Hornung, a business development manager at the company.
He said the collaborations are intended to expand Gore’s capabilities in downstream bioprocessing beyond existing Protein A technologies.
The company’s membrane platform is designed to support multiple stages of bioprocessing, from research and development through large-scale manufacturing, with features including high binding capacity and consistent performance.
“Our high-productivity membranes are designed to deliver consistent high speed, capacity, and reliability at scale,” said Jeff Cassel, chromatography director for Gore PharmBIO Products.
Gore said additional product developments are expected as it continues to expand its membrane chromatography portfolio.
More information is available at www.gore.com/capturemoremAbs.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.